Identity
This entry covers palmitoyl pentapeptide-4 (pal-KTTKS); other Matrixyl-branded blends require separate evaluation.
Selected study only; not a complete clinical review.
Peptide library
Matrixyl
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The randomized split-face design helps control participant differences, but tests a specific moisturizer and cosmetic endpoints. It does not establish all products sold under the Matrixyl family or injectable benefit.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
93 women aged 35–55; 12-week randomized split-face study.
What the sources found
The tested moisturizer improved assessed wrinkles versus its control formulation. This does not validate every product bearing the brand name.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
This entry covers palmitoyl pentapeptide-4 (pal-KTTKS); other Matrixyl-branded blends require separate evaluation.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- The tested topical formulation was reported well tolerated; injectable safety was not studied.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The tested moisturizer improved assessed wrinkles versus its control formulation. This does not validate every product bearing the brand name.
Selected study only; not a complete clinical review.
Adverseeffects
The tested topical formulation was reported well tolerated; injectable safety was not studied.
Selected study only; not a complete clinical review.
References
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. 2005.
PMID: 18492182
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.